The Biostatistics Core (BC) provides statistical collaboration and data management support for each of theSPORE projects, the Developmental Research Program projects, the Career Development Program, and theother Cores. In the past funding period, the BC supported research, and established the infrastructure to linkthe Tissue and Patient Registry Cores. For this competitive renewal, the BC prepared the statistical plans foreach of the four Projects, will provide data management for each of the projects, and will prepare datasummaries for manuscript preparation. Each of the projects presented in this application reflects input frommembers of the BC on study design, and analysis plan. These projects span a wide range of approachesand analyses required. The BC builds upon the innovative and time-tested procedures and systemsdeveloped by Mayo Clinic, one of the largest statistical groups in the country whose members havecollaborated on more than 10,000 clinical and basic science research studies since 1966. The BC hascapability to provide statistical support across different fields, including molecular epidemiologic studies,basic science with translational, immunologic, and correlative studies, gene microarray and imaging, clinicaltrials, gene and mutation discovery, and information management. The comprehensive nature of the BCassures each SPORE investigator access to statistical expertise that includes collaborative development ofstudy designs and analysis plans, state-of-the-art data analysis and interpretation, data managementresources, and abstract and manuscript preparation. The BC also provides a mechanism for themanagement and integration of both existing and newly collected data through consistent and compatibledata handling. Areas of support include database development, data form development and processing, datacollection and entry, data archiving, quality control, and management of information relating to the projectsand cores. This Core complements and assists the efforts of the Clinical Research and Tissue Cores byproviding superior data management and experience with tissue registries. The strengths of the BC are ourcollaboration with each of the projects and cores, the ability to utilize the established centralized researchdatabase, the operational and statistical infrastructure already in place in the SPORE, and the breadth ofexpertise provided by BC personnel.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA102701-06
Application #
7510970
Study Section
Special Emphasis Panel (ZCA1-GRB-I (M1))
Project Start
2008-07-01
Project End
2013-06-30
Budget Start
2008-07-01
Budget End
2009-08-31
Support Year
6
Fiscal Year
2008
Total Cost
$116,369
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Orozco, Carlos A; Martinez-Bosch, Neus; Guerrero, Pedro E et al. (2018) Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk. Proc Natl Acad Sci U S A 115:E3769-E3778
Radecki Breitkopf, Carmen; Wolf, Susan M; Chaffee, Kari G et al. (2018) Attitudes Toward Return of Genetic Research Results to Relatives, Including After Death: Comparison of Cancer Probands, Blood Relatives, and Spouse/Partners. J Empir Res Hum Res Ethics 13:295-304
Antwi, Samuel O; Fagan, Sarah E; Chaffee, Kari G et al. (2018) Risk of Different Cancers Among First-degree Relatives of Pancreatic Cancer Patients: Influence of Probands' Susceptibility Gene Mutation Status. J Natl Cancer Inst :
Cobo, Isidoro; Martinelli, Paola; Flández, Marta et al. (2018) Transcriptional regulation by NR5A2 links differentiation and inflammation in the pancreas. Nature 554:533-537
Razidlo, Gina L; Burton, Kevin M; McNiven, Mark A (2018) Interleukin-6 promotes pancreatic cancer cell migration by rapidly activating the small GTPase CDC42. J Biol Chem 293:11143-11153
Chaker, Mahmoud; Minden, Audrey; Chen, Suzie et al. (2018) Rho GTPase effectors and NAD metabolism in cancer immune suppression. Expert Opin Ther Targets 22:9-17
Sugimoto, Motokazu; Farnell, Michael B; Nagorney, David M et al. (2018) Decreased Skeletal Muscle Volume Is a Predictive Factor for Poorer Survival in Patients Undergoing Surgical Resection for Pancreatic Ductal Adenocarcinoma. J Gastrointest Surg 22:831-839
Danai, Laura V; Babic, Ana; Rosenthal, Michael H et al. (2018) Altered exocrine function can drive adipose wasting in early pancreatic cancer. Nature 558:600-604
Paradise, Brooke D; Barham, Whitney; Fernandez-Zapico, Martín E (2018) Targeting Epigenetic Aberrations in Pancreatic Cancer, a New Path to Improve Patient Outcomes? Cancers (Basel) 10:
Hogan, Kelly A; Cho, Dong Seong; Arneson, Paige C et al. (2018) Tumor-derived cytokines impair myogenesis and alter the skeletal muscle immune microenvironment. Cytokine 107:9-17

Showing the most recent 10 out of 336 publications